Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week with the latest in expansion plans across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). Which companies are making the news?

Below are the news announcements from companies taking to the podium at the DCAT Member Company Announcement Forum held on March 20, 2023, at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT). A further roundup of other DCAT Member Companies making the news thus far in 2023 will be featured in the April 7, 2023, issue of DCAT Value Chain Insights.

• Samsung Biologics Investing $1.5 Bn for New Biomanufacturing Facility

• Bachem Proceeds with Billion-Dollar Plus Investment Plan

• Siegfried Expands Drug-Product and Small-Molecule API Capacity

• WuXi Biologics’ Growing Global Footprint

• Lonza Outlines Expansions in Drug Products, ADCs, mRNA. Products, Lipid Nanoparticles

• Catalent Outlines $652 M-Plus Expansion Plan, Including Integration of $475-M Acquisition of Metrics Contract Services

• Thermo Fisher Scientific Outlines Multi-Segment Expansions

• WuXi STA Outlines Major Expansion Plans

• BSP Pharmaceuticals Details $349-M Expansion Plan

• Granules Investing $250 M for New Green Small-Molecule API Mfg Facility

• Flamma Investing $200 M for Small-Molecule API Expansions

• Porton Pharma Solutions Expanding Drug-Substance and Drug-Product Capacity 

• INCOG BioPharma Services Plans Additional Filling Capacity for Injectables

• Kindeva Drug Delivery and Meridian Medical Technologies Merge To Create New Drug–Device CDMO